Clinical Study of Novel Skin Biomarker Test for Alzheimer’s Disease Gains Vigorous Physician Support in Long-Sought Early Detection Breakthrough
Author of publication
Frederick Huie, MD, Medical DIrector, CVS/Aetna and Advisory Council Member, SYNAPS Dx Scott C. Howell, D.O.
DISCERN™ PKCƐ Assay for Alzheimer’s Disease Measuring synaptic dysfunction to inform a highly accurate diagnose Alzheimer’s Dementia in early dementia.
Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients
The Burden of Diagnosis: How physicians confront diagnosing Alzheimer’s disease with influx of patients seeking disease modifying therapies
FDA Approval of New Drug for Alzheimer’s Disease Underscores Need for DISCERN™ Accurate Diagnostic Testing Prior to Prescribing LEQEMBI™ and Finalizing Coverage
Honoring Caregivers, Patients and Families During Caregivers and Alzheimer’s Awareness Month
SYNAPS Dx Publishes First Autopsy-Confirmed Results for Identifying Alzheimer’s in Presence of Other Co-Morbid Pathologies Using DISCERN™ Test
Spotlighting Accurate, Early Diagnosis of Alzheimer’s Disease: World Alzheimer’s Month
Input your search keywords and press Enter.